Rapid infusion with rituximab: Short term safety in systemic autoimmune diseases

Rheumatology International

Volumn 33, Issue 2, 2013, Pages 529-533

  Larsen, Janni Lisander ^a   Jacobsen, Soren ^a  

^a Rigshospitalet   (Denmark)

Author keywords

Infusion time; Infusion related reaction; Rituximab administration; Systemic autoimmune disease

Indexed keywords

FEXOFENADINE; PARACETAMOL; PREDNISOLONE; RITUXIMAB;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INFUSION RELATED REACTION; MAJOR CLINICAL STUDY; MALE; PILOT STUDY; PRIORITY JOURNAL; RHINITIS; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; AUTOIMMUNE DISEASES; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED;

EID: 84873990787     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-011-2208-0     Document Type: Article

References (16)

1. Keystone E, Fleischmann R, Emery P, Furst DE, van Vollenhoven R, Bathon J, Dougados M, Baldassare A, Ferraccioli G, Chubick A, Udell J, Cravets MW, Agarwal S, Cooper S, Magrini F (2007) Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 56(12):3896-3908
2. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, Hessey EW, Shaw T, Totoritis MC, Reflex Trial Group (2006) Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomised, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at 24 weeks. Arthritis Rheum 54(9):2793-2806
3. Gottenberg JE, Guillevin L, Lambotte O, Combe B, Allanore Y, Cantagrel A, Larroche C, Soubrier M, Bouillet L, Dougados M, Fain O, Farge D, Kyndt X, Lortholary O, Masson C, Moura B, Remy P, Thomas T, Wendling D, Anaya JM, Sibilia J, Mariette X, Club Rheumatismes et Inflamation (CRI) (2005) Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 64(6):913-920
4. Salar A, Casao D, Cervera M, Pedro C, Calafell M, Abella E, Alvarez-Larran A, Besses C (2006) Rapid infusion of rituximab with or without steroid-containing chemotherapy: 1-yr experience in a single institution. Eur J Haematol 77(4):338-340
5. Tuthill M, Crook T, Corbet T, King J, Webb A (2009) Rapid infusion of rituximab over 60 min. Eur J Haematol 82(4):322-325
6. Zahrani A, Ibrahim N, Al Eid A (2009) Rapid infusion rituximab changing practice for patient care. J Oncol Pharm Pract: Off Publ Int Soc Oncol Pharm Pract 15(3):183-186
7. Provencio M, Cerdeira S, Bonilla F, Sanchez A, Espana P (2006) Rapid-infusion rituximab in lymphoma treatment. Ann Oncol: Off J Eur Soc Med Oncol/ESMO 17(6):1027-1028
8. Sehn LH, Donaldson J, Filewich A, Fitzgerald C, Gill KK, Runzer N, Searle B, Souliere S, Spinelli JJ, Sutherland J, Connors JM (2007) Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting. Blood 109(10):4171-4173
9. Aurran-Schleinitz T et al (2005) "One hour" rituximab infusion is safe and improves patient care and outpatient unit management. Blood 106(11). Abstract no 4759
10. Bukh G, Larsen S, Rasmussen S, Mølgård M, Hansen M (2008) Accelerated infusion-rate of rituximab for rheumatoid arthritis is well tolerated and safe. Am Coll Rheumatol Ann Meet. San Franc. Abstract no 1885. Board no 607
11. Gibbs s (2007). Norfolk and Norwich University Hospital, Norwich. Rapid infusion rituximab is as effective and safe as conventional infusion regimes in the treatment of diffuse large B-cell lymphoma. A 2 year prospectus study. Haematol 92(Suppl 2):264. Abstract no 0708
12. Scoeffel DA et al (2008) Simplified treatment protocol of rituximab in rheumatoid arthritis. Ann Rheum Dis 67(Suppl II):337. Abstract (FRI0161)
13. Bukh G, Larsen S, Rasmussen S, Mølgård M, Hansen M (2011) Very fast infusion-rate of rituximab for rheumatoid arthritis is well tolerated and safe. Ann Rheum Dis 70(Suppl 3):754. Abstract
14. Siano M, Lerch E, Negretti L, Zucca E, Rodriguez-Abreu D, Oberson M, Leoncini L, Mora O, Sessa C, Gallino A, Ghielmini M (2008) A phase I-II study to determine the maximum tolerated infusion rate of rituximab with special emphasis on monitoring the effect of rituximab on cardiac function. Clin Cancer Res: Off J Am Assoc Cancer Res 14(23):7935-7939
15. Taylor SR, Salama AD, Joshi L, Pusey CD, Lightman SL (2009) Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis. Arthritis Rheum 60(5):1540-1547
16. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13(3):176-181